Key result
Greater syndecan-1 changes during hemodialysis are linked to higher intradialytic hypotension risk.
Why the study?
The relationship between vascular endothelial glycocalyx dysfunction, indicated by serum syndecan-1 levels, and intradialytic hypotension during hemodialysis was unclear.
Is the change in serum syndecan-1 concentration during hemodialysis associated with intradialytic hypotension in patients undergoing outpatient hemodialysis?
Observational (n=92)
No
Is the change in serum syndecan-1 concentration during hemodialysis associated with intradialytic hypotension in patients undergoing outpatient hemodialysis?
Odds Ratio: 1.005 (95% CI 1.001–1.009)
p-value: p=0.006
Changes in serum syndecan-1 levels during hemodialysis correlate with intradialytic hypotension, suggesting vascular endothelial glycocalyx impairment may play a causal role.
Syndecan-1 change may mark glycocalyx injury during hemodialysis; leaves open predictive utility and causal interventions.
Intradialytic hypotension and arrhythmias are complications of hemodialysis. They are associated with decreased intravascular volume due to reduced ultrafiltration volume, cardiac function, and arterial tone. The vascular endothelial glycocalyx, which exists on the surface of healthy vascular endothelial cells and maintains vascular permeability, has been suggested to be impaired by hemodialysis. This single-center retrospective study evaluated the association between syndecan-1, an endothelial glycocalyx dysfunction marker, and complications of hemodialysis. We enrolled 92 patients who underwent outpatient hemodialysis at Gifu Seiryu Hospital from April to July 2022 (346 hemodialysis sessions). The median duration and time of hemodialysis were 40 months and 4.1 h, respectively. Median serum syndecan-1 levels were 67.7 ng/mL before and 98.3 ng/mL after hemodialysis. Hemodialysis complications were noted in 68 sessions, all of which were hypotension. No correlation between pre-hemodialysis syndecan-1 levels and the incidence of complications was observed. However, a positive correlation between the amount of change in syndecan-1 levels before and after hemodialysis and the incidence of hemodialysis complications was noted. Conversely, syndecan-1 levels did not correlate with brain or atrial natriuretic peptides, suggesting that impairment of the vascular endothelial glycocalyx may be a possible cause of intradialytic hypotension and may be useful in preventing intradialytic hypotension.
No takes yet. Share an insight, caveat, or question.
Oiwa et al. (2023) conducted an observational in End-stage renal failure undergoing hemodialysis (n=92). Change in serum syndecan-1 concentration was evaluated on Hemodialysis complications (intradialytic hypotension) (OR 1.005, 95% CI 1.001-1.009, p=0.006). A greater change in serum syndecan-1 concentration before and after hemodialysis was significantly associated with a higher occurrence of intradialytic hypotension (OR 1.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: